The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 5, 2015, Pages 578-584

  Corneli, Amy L ^a   McKenna, Kevin ^a   Perry, Brian ^a   Ahmed, Khatija ^b   Agot, Kawango ^c   Malamatsho, Fulufhelo ^b   Skhosana, Joseph ^b   Odhiambo, Jacob ^c   Van Damme, Lut ^a,d  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b Setshaba Research Centre   (South Africa)

^c IMPACT RESEARCH AND DEVELOPMENT ORGANIZATION   (Kenya)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

adherence; Africa; FEM PrEP; measurement; pre exposure prophylaxis; women

Indexed keywords

EMTRICITABINE; PLACEBO; TENOFOVIR DISOPROXIL; ADENINE; DEOXYCYTIDINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KENYA; MARRIAGE; MEDICATION COMPLIANCE; PILL; PLACEBO EFFECT; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SCREENING; SELF REPORT; SEMI STRUCTURED INTERVIEW; SOUTH AFRICA; ANALOGS AND DERIVATIVES; HIV INFECTIONS; INTERVIEW; TREATMENT OUTCOME;

ADENINE; ADULT; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; KENYA; MEDICATION ADHERENCE; ORGANOPHOSPHONATES; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 84925037466     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000525     Document Type: Article

References (34)

1. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367: 411-422.
2. Corneli A, Deese J, Wang M, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily, oral study product for preexposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66:324-331.
3. FHI 360. FHI to initiate orderly closure of FEM-PrEP. 2011. Available at: www.fhi360.org/fhi-statement-fem-prep-hiv-prevention-study. Accessed June 10, 2014.
4. Agot K, Taylor D, Corneli A, et al. Accuracy of self-report and pill-count measures of adherence in the FEM-PrEP clinical trial: implications for future HIV-prevention trials. AIDS Behavior. Aug 7, 2014.
5. Taylor D, Amico KR, Brown E. Asking about and measuring adherence. Paper presented at: The International Microbicides Conference; April 15-18, 2012; Sydney, Australia.
6. Amico KR, Marcus JL, McMahan V, et al. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014;17(6):2143-2155.
7. van der Straten A, Brown EB, Marrazzo JM, et al. Divergent adherence Estimates with Pharmacokinetic and Behavioral measures in VOICE (MTN003) [#44]. Paper presented at: The 21st Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA.
8. Donnell D, Baeten JM, Bumpus NN, et al. HIV Protective Efficacy and Correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340-348.
9. Amico KR, Mansoor LE, Corneli A, et al. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behavior. 2013;17: 2143-2155.
10. Adams JL, Sykes C, Menezes P, et al. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? J Acquir Immune Defic Syndr. 2013;62:260-266.
11. Corneli A, Perry B, Agot K, et al. FEM-PrEP: participant explanations for non-adherence [#959LB]. Paper presented at: The 21st Conference on Retroviruses and Opportunistic Infections March 3-6, 2014; Boston, MA. Available at: http://www.croi2014.org/sessions/fem-prep-participantexplanations-non-adherence. Accessed on November 21, 2014.
12. Corneli A, Perry B, Ahmed K, et al. FEM-PrEP: participant explanations for study product adherence [#366]. Paper presented at: The 9th International Conference on HIV Treatment and Prevention Adherence June, 2014; Miami, FL. Available at: http://iapac.org/AdherenceConference/presentations/ADH9-OA366.pdf. Accessed on November 21, 2014.
13. Mensch BS, Hewett PC, Jones HE, et al. Consistency in women's reports of sensitive behavior in an interview mode experiment, Sao Paulo, Brazil. Int Fam Plan Perspect. 2008;34:169-176.
14. Fisher RJ. Social desirability bias and the validity of indirect questioning. J Consum Res. 1993;20:303-315.
15. Guest G, Macqueen KM, Namey EE. Applied Thematic Analysis. Thousand Oaks, CA: SAGE Publications, Inc.; 2012.
16. NVivo Qualitative Data Analysis Software: QSR International Pty Ltd. Version 10; 2012.
17. Chillag K, Guest G, Bunce A, et al. Talking about sex in Botswana: social desirability bias and possible implications for HIV-prevention research. Afr J AIDS Res. 2006;5:123-131.
18. Guest G, Bunce A, Johnson L, et al. Fear, hope and social desirability bias among women at high risk for HIV in West Africa. J Fam Plann Reprod Health Care. 2005;31:285-287.
19. Geary CW, Tchupo JP, Johnson L, et al. Respondent perspectives on self-report measures of condom use. AIDS Educ Prev. 2003;15:499-515.
20. Gallo MF, Steiner MJ, Hobbs MM, et al. Predictors of unprotected sex among female sex workers in Madagascar: comparing semen biomarkers and self-reported data. AIDS Behavior. 2010;14:1279-1286.
21. Wilson IB, Carter AE, Berg KM. Improving the self-report of HIV antiretroviral medication adherence: is the glass half full or half empty? Curr HIV/AIDS Rep. 2009;6:177-186.
22. Williams AB, Amico KR, Bova C, et al. A proposal for quality standards for measuring medication adherence in research. AIDS Behavior. 2013; 17:284-297.
23. Wilson I, Fowler J, Cosenza C, et al. Lessons from Cognitive testing of self-report adherence Items. Paper presented at: 7th International Conference on HIV Treatment and Prevention Adherence June 3-5; 2012; Miami, FL.
24. Servick K. Biomedicine. "Nonadherence": a bitter pill for drug trials. Science. 2014;346:288-289.
25. Crowne DP, Marlowe D. A new scale of social desirability independent of psychopathology. J Consult Psychol. 1960;24:349-354.
26. Vu A, Tran N, Pham K, et al. Reliability of the Marlowe-Crowne social desirability scale in Ethiopia, Kenya, Mozambique, and Uganda. BMC Med Res Methodol. 2011;11:162.
27. Wong C, Parker C, Ahmed K, et al. Participant motivation for enrolling and continuing in the FEM-PrEP HIV prevention clinical trial [#WEAC0104]. Paper presented at: The 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3 2013; Kuala Lumpur.
28. Participants in the 2006 Georgetown University Workshop on the Ancillary-Care Obligations of Medical Researchers Working in Developing Countries. The ancillary-care obligations of medical researchers working in developing countries. PLoS Med. 2008;5:e90.
29. Macqueen KM, McLoughlin K, Alleman P, et al. Partnering for care in HIV prevention trials. J Empir Res Hum Res Ethics. 2008;3:5-18.
30. Joint United Nations Programme on HIV/AIDS (UNAIDS), & World Health Organization (WHO). Ethical Considerations in Biomedical HIV Prevention Trials, Geneva, Switzerland: UNAIDS/WHO Guidance Document; 2012.
31. Stuart R, Sugarman J; the HPTN Ethics Working Group. HIV Prevention Trials Network (HPTN) Ethics Guidance for Research. 2009.
32. Belsky L, Richardson HS. Medical researchers' ancillary clinical care responsibilities. BMJ. 2004;328:1494-1496.
33. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
34. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511.